Sanofi immune drug hopeful posts mixed results in mid-stage tests

April 7, 2026

BioPharma Dive

Lunsekimig, a bispecific drug aimed at two popular targets, succeeded in studies in asthma and nasal polyps but missed its mark in an eczema trial.